MSC therapy significantly reduces fasting and postprandial blood glucose, HbA1c, and insulin requirements while improving C‐peptide levels and insulin resistance with mild and manageable symptoms like fever, nausea, headache, and minor hypoglycemia [159, 160]. This evidence concerns the gene INS and Hypoglycemia.